Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire
Protalix BioTherapeutics announces significant milestones in 2024, including EMA validation for a less frequent dosing regimen for Fabry disease, progress in PRX-115 clinical trials, and repayment of all outstanding convertible notes, positioning the company for long-term growth.
Highlighted Terms
Elelyso®Brazilian Ministry of Healthpegunigalsidase alfaEuropean Medicine AgencyChiesi Global Rare DiseasesPRX 115Fundação Oswaldo CruzAmerican College of RheumatologyElfabrio®Protalix BioTherapeuticsPfizer Inc.PRX–119Chiesi Farmaceutici S.p.A.NETs-related diseasesFabry diseaseUplyso®uncontrolled gout
Related News
Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire
Protalix BioTherapeutics announces significant milestones in 2024, including EMA validation for a less frequent dosing regimen for Fabry disease, progress in PRX-115 clinical trials, and repayment of all outstanding convertible notes, positioning the company for long-term growth.